NCT05549661 2026-02-23
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
Mayo Clinic
Phase 1 Recruiting
Mayo Clinic
Mayo Clinic
University of Southern California
Mayo Clinic
Mayo Clinic
National Cancer Institute (NCI)
Mayo Clinic